Investigational drug · Phase 2
CRT-402
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Scleroderma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "CRT-402"
First trial start
2026
Aug 26, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CRT-402", any sponsor or status.
Conditions studied
As listed on its trial records.
- Autoimmune Diseases
- Systemic Lupus Erythematosus
- Systemic Scleroderma
- Myositis
Approved drugs for the same conditions: Lupus (SLE) · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "CRT-402" as an intervention, largest first.
Myeloid TherapeuticsIndustry
NCT07778446 · 34 participants (planned) · Start Aug 26, 2026 · Primary completion Dec 1, 2028
Drug: CRT-402 · For: Autoimmune Diseases; Systemic Lupus Erythematosus; Systemic Scleroderma and 1 more
Sites: Nedlands, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Autoimmune Diseases
- C-CAR168Phase 22 trials
AbelZeta Inc. · Lupus Nephritis (LN), Systemic Lupus Erythematosus (SLE), Autoimmune Diseases
- IfetrobanPhase 22 trials
Cumberland Pharmaceuticals · Scleroderma, Diffuse, Scleroderma, Systemic, Scleroderma, Limited
- ATH-063Phase 21 trial
Athos Therapeutics Inc · Ulcerative Colitis, Inflammatory Bowel Diseases, Autoimmune Diseases
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.